Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

Autor: Shablack, Alaaeldin, O'Callaghan, Ann, Moody, (Margaret) Anne, Allen, Alex, Brewster, Alison, Brown, Alison, Mayer, Astrid, Davidson, Brian, Ton, Chan, Wilson, Charles, Lowdell, Charles, Rees, Charlotte, Baughan, Christopher, Barlow, Clare, Purcell, Colin, Smith, David, Tsang, David, Brown, Ewan, Walker, Georgina, Malik, Hassan, Cameron, Iain, Nolan, Luke, Hall, Marcia, Tomlinson, Marjorie, Hill, Mark, Peterson, Mark, Finch-Jones, Meg, Kumar, Nagappan, Karanjia, Nariman, Ali, Nasim, Heaton, Nigel, Ton, Nua Chan, Ross, Paul, Praseedom, Raaj, Thomas, Robert, Clive, Sally, Slater, Sarah, Smith, Sarah, Mudan, Satvinder, Bhattacharya, Satya, Essapen, Sharadah, Raouf, Sherif, Fenwick, Stephen, Cleator, Susan, Diamond, Tom, Potter, Vanessa, Bridgewater, John A, Pugh, Siân A, Maishman, Tom, Eminton, Zina, Mellor, Jane, Whitehead, Amy, Stanton, Louise, Radford, Michael, Corkhill, Andrea, Griffiths, Gareth O, Falk, Stephen, Valle, Juan W, O'Reilly, Derek, Siriwardena, Ajith K, Hornbuckle, Joanne, Rees, Myrddin, Iveson, Timothy J, Hickish, Tamas, Garden, O James, Cunningham, David, Maughan, Timothy S, Primrose, John N ^*

Publikováno v: In The Lancet Oncology March 2020 21(3):398-411

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Autor: Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengy, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., Paul, James

Publikováno v: Iveson, T J, Kerr, R S, Saunders, M P, Cassidy, J, Hollander, N H, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K A, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A S, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R K, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H S & Paul, J 2018, ' 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial ', Lancet Oncology, vol. 19, no. 4, pp. 562-578 . https://doi.org/10.1016/S1470-2045(18)30093-7

Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2d57e07e4b86c46d7bdc8853680f2d02
https://doi.org/10.1016/s1470-2045(18)30093-7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Mechanisms of osteolysis in bone metastases secondary to breast cancer

Autor: Iveson, Timothy John

Externí odkaz: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.362775